

Please add the following claims:

17 ~~16~~ (New) The method according to Claim ~~2~~¹⁶, wherein the viral condition is selected from the group consisting of herpes varicella and herpes zoster.

18 ~~20~~ (New) The method according to Claim ~~19~~¹⁷, wherein the viral condition is herpes varicella.

19 ~~21~~ (New) The method according to Claim ~~19~~¹⁷, wherein the viral condition is herpes zoster.

REMARKS

Claim 1 has been amended to clearly point out and distinctly claim what Applicant regards as the subject matter of the present invention. Claim 1 has been amended to recite that systemic host defense mechanisms are stimulated and incorporates the limitation of canceled claim 6. Support for the amendment may be found at, for example, page 18, lines 22-26.

New claims 19-20 are directed to the treatment of certain viral infections. Support for the new claims may be found at, for example, page 5, lines 17-22.

Claim 13 is drawn to a method that uses an interferon comprising a Type II interferon. Claim 14 further limits the Type II interferon to a gamma-interferon. Type II interferons comprise the genus and the gamma interferon is the species. As noted in our response in the previous application, the possibility that there may exist other Type II interferons should not be precluded. Subsequent discovery of another Type II interferon would not be covered if Applicant canceled claim 13. In an infringement action, equivalents are determined at the time of infringement; Applicant believes that the genus, Type II interferon, is broader than the species, gamma interferon, because there can be more than one species encompassed by the genus. If Applicant were required to choose one claim over the other it would be to their detriment. Thus, Applicant is entitled to